GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » Valuation Rank
中文

Bavarian Nordic A/S (Bavarian Nordic A/S) Valuation Rank


View and export this data going back to 2013. Start your Free Trial

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bavarian Nordic A/S Valuation Rank Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » Valuation Rank
Comparable Companies
OCSE:GUBRA OCSE:PEG OCSE:ALK B OCSE:ZEAL OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX OCSE:GMAB ALNY BGNE BMRN SZSE:300122 RPRX
Traded in Other Exchanges
BVNKF:USA BAVAc:UK 0DPB:UK BAVA:Denmark BV3:Germany
Address
Philip Heymans Alle 3, Hellerup, DNK, DK-2900
Website
https://www.bavarian-nordic.com
Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.